Khiron Life Sciences Receives Endorsement from Prominent Colombian Medical Association for the Study of Pain
Khiron Life Sciences Corp. (TSXV:KHRN), (OTCQB:KHRNF), (Frankfurt:A2JMZC) (“Khiron” or the “Company”) , an integrated medical cannabis company with its core operations in Colombia, is pleased to announce it has signed an endorsement agreement with the highly respected and influential Colombian Association for the Study of Pain (ACED). In endorsing Khiron’s patient-focused approach to medical cannabis research and product development, ACED has committed to partnering with the Company on a schedule of patient and physician education programs, modules and events.
Formed as a chapter of the Washington, D.C.-based International Association for the Study of Pain (IASP), ACED is a 300-member interdisciplinary association of physicians whose goal is to study and harmonize all aspects of the research, diagnosis and treatment of pain in Colombia, under the guidelines of the International Association.
Khiron will collaborate with ACED to advance physician education and knowledge about safe and effective pain treatments for patients. This includes exploring opportunities for joint continuing education efforts for doctors, the organization of international congresses, regional and satellite professional development courses, and functional integration with other scientific societies throughout Colombia and Latin America.
Dr. Maria Fernanda Arboleda, Khiron Medical Director, and pain and palliative care specialist, stated: “ACED’s endorsement of Khiron gives us access to educate pain specialists on how medical cannabis can have a positive impact on patients living with pain-related conditions. ACED’s relationship with international organizations such as the International Narcotics Control Board, the Pan American Health Organization and the United Nations, among others, positions Khiron among a global pain management community as we explore and open new medical cannabis opportunities throughout Latin America.”
Khiron will be a presenting partner at ACED’s XXVIII International Congress of Pain, being held Bogotá, Colombia from May 16 to 18, 2019. This event will offer a variety of educational modules focused on the study and treatment of pain in Colombia, including a growing body of evidence around the efficacy of medical cannabis products.
About the Colombian Association for the Study of Pain (ACED)
The Colombian Association for the Study of Pain (ACED) is an interdisciplinary non-profit association, formed in 1992 and headquartered in Bogotá, that brings together health and science professionals who investigate and treat pain in Colombia and who work collaboratively with private industry and other parties with professional interest in this important area of medical research and patient care.
ACED’s national initiatives include the National Survey of Pain, the National Pain Network and the “Hospitals without Pain” campaign which aims to make it a fundamental constitutional right of Colombians to have access to pain-free medical care and for medical professionals to have the right to treat pain and reduce human suffering through the safest scientifically-validated means possible.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. (TSXV: KRHN, OTCQB: KHRNF, Frankfurt: A2JMZC) (“Khiron” or the “Company”) is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming one of the first Colombian based medical cannabis companies to trade on any exchange globally.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/
This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Filing Statement which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.